Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs OurView Health

Maves
Graded #88

Higher grade

vs+4.200000000000003
OurView Health
Graded #167

Lower grade

The verdict

Maves takes it — 71.8/100 to 67.6/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +8
84
76
Dose & formulationMaves +1
65
64
Clinical oversightOurView Health +3
76
79
Labs & monitoringOurView Health +1
52
53
FulfillmentMaves +17
87
70
Contract termsMaves +10
55
45
Maves · left barOurView Health · right bar

The numbers

MetricMavesOurView Health
WeighScore71.8/10067.6/100
GradeCC
Scorecard rank#88#167
Semaglutide$99/mo (starting dose, first-month rate, compounded)$75/mo (starting dose, compounded)
TirzepatideNot disclosed$135/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
OurView Health

Graded #167 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • 'Starting at' prices likely require Savings Club membership and/or a longer plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • 'LegitScript Approved' is stated on the site but was not independently verified here
  • Operating medical entity not clearly named (site operated by a marketing agency)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard